1. Home
  2. BIP vs UTHR Comparison

BIP vs UTHR Comparison

Compare BIP & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIP
  • UTHR
  • Stock Information
  • Founded
  • BIP 2007
  • UTHR 1996
  • Country
  • BIP Bermuda
  • UTHR United States
  • Employees
  • BIP N/A
  • UTHR N/A
  • Industry
  • BIP Marine Transportation
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • BIP Consumer Discretionary
  • UTHR Health Care
  • Exchange
  • BIP Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • BIP 15.8B
  • UTHR 13.8B
  • IPO Year
  • BIP 2008
  • UTHR 1999
  • Fundamental
  • Price
  • BIP $34.63
  • UTHR $458.23
  • Analyst Decision
  • BIP Strong Buy
  • UTHR Buy
  • Analyst Count
  • BIP 4
  • UTHR 15
  • Target Price
  • BIP $43.50
  • UTHR $459.60
  • AVG Volume (30 Days)
  • BIP 604.0K
  • UTHR 845.8K
  • Earning Date
  • BIP 11-07-2025
  • UTHR 10-29-2025
  • Dividend Yield
  • BIP 4.97%
  • UTHR N/A
  • EPS Growth
  • BIP N/A
  • UTHR 17.94
  • EPS
  • BIP 0.08
  • UTHR 25.63
  • Revenue
  • BIP $21,535,000,000.00
  • UTHR $3,077,800,000.00
  • Revenue This Year
  • BIP N/A
  • UTHR $13.71
  • Revenue Next Year
  • BIP N/A
  • UTHR $5.38
  • P/E Ratio
  • BIP $420.51
  • UTHR $17.82
  • Revenue Growth
  • BIP 8.86
  • UTHR 17.62
  • 52 Week Low
  • BIP $25.72
  • UTHR $266.98
  • 52 Week High
  • BIP $36.50
  • UTHR $458.94
  • Technical
  • Relative Strength Index (RSI)
  • BIP 76.36
  • UTHR 73.07
  • Support Level
  • BIP $32.82
  • UTHR $415.00
  • Resistance Level
  • BIP $31.37
  • UTHR $442.01
  • Average True Range (ATR)
  • BIP 0.67
  • UTHR 13.27
  • MACD
  • BIP 0.31
  • UTHR 0.14
  • Stochastic Oscillator
  • BIP 94.81
  • UTHR 99.14

About BIP Brookfield Infrastructure Partners LP

Brookfield Infrastructure Partners LP is a Bermuda exempted limited partnership that owns and operates quality, long-life assets that generate stable cash flows, by virtue of barriers to entry or other characteristics that tend to appreciate in value over time. It focuses on acquiring infrastructure assets that have low maintenance capital costs and high barriers to entry. The company's segments consist of Utilities, Transport, Midstream, and Data. Geographically, it generates maximum revenue from USA and also has a presence in Australia, Colombia, United Kingdom, Brazil, United States of America, Chile, Peru, and other countries.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: